The trial posting for A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) 0.1, 0.4, and 0.8 mg as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated with Bipolar 1 Disorder in Adult Subjects is not listed as active in clinicaltrials.partners.org database. The trial may have stopped recruiting.